𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer

✍ Scribed by Kathy D. Miller; Sharon E. Soule; LaTrice G. Haney; Patricia Guiney; Darryl J. Murry; Luigi Lenaz; Show-Li Sun; George W. Sledge

Book ID
111579886
Publisher
Springer US
Year
2004
Tongue
English
Weight
64 KB
Volume
22
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of ionidamine in patients
Phase II study of ionidamine in patients with metastatic breast cancer
✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi

Trimetrexate in untreated and previously
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study
✍ Dawson, Nancy A. ;Costanza, Mary E. ;Korzun, Ann H. ;Clamon, Gerald H. ;Pollak, πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 554 KB

Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX). Patients received TMTX 8 mg/m2/day if previously treated or 12 mg/m2/day if previously untreated, both given by intravenous bol